12 дек. 2022 г. · The OPERA-TAVI registry showed that SE and BE devices had comparable Valve Academic Research Consortium-3 device success rates, but the BE ...

We aimed to compare 1-year clinical outcomes of TAVI patients receiving Evolut PRO/PRO+ (PRO) or SAPIEN 3 Ultra (ULTRA) devices in current real-world practice.

The OPERA-TAVI registry showed that SE and BE devices had comparable Valve Academic Research Consortium-3 device success rates, but the BE device had a higher ...

One-year clinical outcomes of patients undergoing transfemoral TAVI and receiving PRO or ULTRA devices in the current clinical practice were similar.

11 мар. 2024 г. · Data from the OPERA-TAVI (Comparative Analysis of Evolut PRO vs. SAPIEN 3 ULTRA Valves for Transfemoral Transcatheter Aortic Valve Implantation) ...

In the OPERA-TAVI registry, no differences in vascular complications and any bleedings were noted in women versus men in both TAV groups and in PRO versus ULTRA ...

12 дек. 2022 г. · The OPERA-TAVI registry showed that SE and BE devices had comparable Valve Academic Research Consortium-3 device success rates, but the BE ...

24 нояб. 2023 г. · The OPERA-TAVI registry reflects real-world usage of the two platforms, and includes newer iterations of the two devices—Evolut PRO and ...

Sex-Related Outcomes of Transcatheter Aortic Valve Implantation with Self-Expanding or Balloon-Expandable Valves: Insights from the OPERA-TAVI Registry.

Consistent with most prior work, OPERA-TAVI found no dif- ference in the primary efficacy outcome of device success (BE. 85.9% v SE 87.4%; p = 0.47), although ...